Objectives: To investigate the osteoinductive efficacy of various types of BMP-2-containing biomimetic calcium phosphate coatings. The criterion for an optimal system is that it elicits a high osteogenic activity at a low drug dose within a short period of time. Methods: Four different delivery modes for BMP-2 were chosed in this study. Initially, the osteoinductive efficacies of BMP-2 deliveryed by calcium phosphate coating bearing adsorbed BMP-2 at three different loading concentrations (2.5 µg, 5.0 µg and 7.5 µg per implant) were tested at an ectopic (subcutaneous) ossification site in rats. Following surgery, the implants (titanium discs) were retrieved 1, 2 or 3 weeks later for histomorphometric analysis. Having ascertained this fact, BMP-2 was incorporated into the crystalline type of coating at three different concentrations (0.56 µg, 0.61 µg and 1.7 µg per implant). We also established a hybrid system: a crystalline coating bearing incorporated BMP-2 at different concentrations and adsorbed BMP-2 at a fixed dose. The implanted samples were retrieved at 2 and 5 weeks. Results: Two weeks after surgery, the amount of bone deposited around calcium phosphate coatings bearing the highest dose of incorporated BMP-2 (1.7 µg per implant) was almost 3-fold higher than that associated with coatings bearing adsorbed BMP-2 at a 3-fold higher dose (5.0 µg per implant), namely, 5.83 mm3 vs. 1.98 mm3 per implant. Using the hybrid system, osteoinductive efficacy was further potentiated in a manner that was proportional to the incorporated dose of BMP-2. Conclusions: The osteoinductive efficacy of BMP-2 can be modulated by its delivery modes.